Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma

Clin Genitourin Cancer. 2016 Feb;14(1):e81-90. doi: 10.1016/j.clgc.2015.07.017. Epub 2015 Aug 7.

¹ Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
² Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
³ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, Cornell University, New York, NY.
⁴ Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
⁵ Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
⁶ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
⁷ Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
⁸ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, Cornell University, New York, NY.
⁹ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: [email protected].

No abstract available

Keywords: Advanced disease; Angiogenesis; Clinical benefit; Next-generation sequencing; Pazopanib.

Publication types